132.39
price up icon1.08%   1.42
 
loading
前日終値:
$130.97
開ける:
$132.24
24時間の取引高:
1.42M
Relative Volume:
0.94
時価総額:
$279.66B
収益:
$53.40B
当期純損益:
$13.68B
株価収益率:
19.22
EPS:
6.8864
ネットキャッシュフロー:
$16.89B
1週間 パフォーマンス:
+7.07%
1か月 パフォーマンス:
+3.24%
6か月 パフォーマンス:
+17.93%
1年 パフォーマンス:
+16.37%
1日の値動き範囲:
Value
$131.95
$133.37
1週間の範囲:
Value
$123.20
$133.37
52週間の値動き範囲:
Value
$96.06
$133.37

Novartis Ag Adr Stock (NVS) Company Profile

Name
名前
Novartis Ag Adr
Name
セクター
Healthcare (1145)
Name
電話
-
Name
住所
-
Name
職員
75,883
Name
Twitter
@novartis
Name
次回の収益日
2025-07-17
Name
最新のSEC提出書
Name
NVS's Discussions on Twitter

NVS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.39 253.54B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
LLY
Lilly Eli Co
839.87 734.96B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
188.64 447.90B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
233.91 417.90B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
MRK
Merck Co Inc
89.19 223.58B 63.43B 16.42B 14.72B 6.4861

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-09-12 ダウングレード Goldman Neutral → Sell
2025-08-08 アップグレード Morgan Stanley Underweight → Equal-Weight
2025-02-13 ダウングレード UBS Buy → Neutral
2025-02-12 開始されました Morgan Stanley Underweight
2025-02-04 アップグレード Deutsche Bank Hold → Buy
2024-12-04 ダウングレード HSBC Securities Hold → Reduce
2024-09-11 ダウングレード BofA Securities Buy → Neutral
2024-09-05 ダウングレード Goldman Buy → Neutral
2024-09-03 ダウングレード Jefferies Buy → Hold
2024-07-19 ダウングレード Deutsche Bank Buy → Hold
2024-05-30 開始されました Goldman Buy
2024-02-23 開始されました BMO Capital Markets Market Perform
2024-01-23 開始されました Morgan Stanley Equal-Weight
2024-01-16 再開されました UBS Buy
2023-12-18 ダウングレード HSBC Securities Buy → Hold
2023-09-25 アップグレード Morgan Stanley Underweight → Equal-Weight
2023-07-14 開始されました HSBC Securities Buy
2023-04-26 アップグレード Deutsche Bank Hold → Buy
2023-03-27 アップグレード Deutsche Bank Sell → Hold
2023-01-26 ダウングレード Citigroup Buy → Neutral
2022-12-05 アップグレード Stifel Hold → Buy
2022-09-15 ダウングレード Credit Suisse Neutral → Underperform
2022-09-14 ダウングレード Berenberg Buy → Hold
2022-05-09 ダウングレード Wolfe Research Outperform → Peer Perform
2022-01-10 再開されました Citigroup Buy
2021-12-14 ダウングレード Redburn Buy → Neutral
2021-12-06 ダウングレード Exane BNP Paribas Outperform → Neutral
2021-12-03 ダウングレード Bryan Garnier Buy → Neutral
2021-09-20 ダウングレード Deutsche Bank Hold → Sell
2021-03-22 開始されました Bernstein Mkt Perform
2021-03-10 ダウングレード Argus Buy → Hold
2021-02-01 ダウングレード Cowen Outperform → Market Perform
2021-01-15 開始されました Deutsche Bank Buy
2020-09-29 開始されました Berenberg Buy
2020-09-10 アップグレード UBS Neutral → Buy
2020-09-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-06-15 アップグレード Citigroup Neutral → Buy
2020-03-10 アップグレード Morgan Stanley Underweight → Equal-Weight
2020-02-25 ダウングレード Guggenheim Buy → Neutral
2019-04-25 アップグレード Guggenheim Neutral → Buy
2019-04-25 アップグレード Liberum Hold → Buy
2019-04-10 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-01-02 ダウングレード JP Morgan Neutral → Underweight
2018-12-11 再開されました Jefferies Buy
2018-10-09 開始されました Guggenheim Neutral
2018-09-10 アップグレード BofA/Merrill Underperform → Buy
2018-05-29 ダウングレード HSBC Securities Buy → Hold
2018-05-25 アップグレード Credit Suisse Underperform → Neutral
2018-01-25 繰り返されました Leerink Partners Outperform
2017-12-06 ダウングレード BofA/Merrill Neutral → Underperform
2017-07-26 アップグレード Morgan Stanley Underweight → Overweight
2017-07-05 ダウングレード Credit Suisse Neutral → Underperform
2017-03-09 開始されました Liberum Buy
すべてを表示

Novartis Ag Adr (NVS) 最新ニュース

pulisher
Oct 04, 2025

2 Surefire Dividend Stocks to Buy for the Long Haul - The Globe and Mail

Oct 04, 2025
pulisher
Sep 30, 2025

Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | DelveInsight - GlobeNewswire Inc.

Sep 30, 2025
pulisher
Sep 25, 2025

Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm

Sep 25, 2025
pulisher
Sep 23, 2025

UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail

Sep 23, 2025
pulisher
Sep 19, 2025

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail

Sep 19, 2025
pulisher
Sep 15, 2025

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm

Sep 15, 2025
pulisher
Sep 13, 2025

UBS Sticks to Their Hold Rating for Novartis AG (NOVN) - The Globe and Mail

Sep 13, 2025
pulisher
Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025
pulisher
Sep 12, 2025

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Sep 12, 2025
pulisher
Sep 11, 2025

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail

Sep 11, 2025
pulisher
Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025
pulisher
Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025
pulisher
Sep 09, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis

Sep 09, 2025
pulisher
Sep 04, 2025

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm

Sep 04, 2025
pulisher
Sep 04, 2025

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail

Sep 04, 2025
pulisher
Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025
pulisher
Sep 03, 2025

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Sep 03, 2025
pulisher
Aug 29, 2025

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm

Aug 29, 2025
pulisher
Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025
pulisher
Aug 19, 2025

Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail

Aug 19, 2025
pulisher
Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025
pulisher
Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025
pulisher
Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Aug 11, 2025
pulisher
Aug 10, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

Aug 10, 2025
pulisher
Aug 07, 2025

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Aug 07, 2025
pulisher
Aug 01, 2025

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - The Globe and Mail

Aug 01, 2025
pulisher
Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025

Novartis Ag Adr (NVS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general MRK
$89.19
price down icon 0.36%
drug_manufacturers_general NVO
$59.63
price up icon 1.52%
$297.89
price up icon 0.16%
drug_manufacturers_general PFE
$27.37
price up icon 1.07%
$233.91
price down icon 1.12%
大文字化:     |  ボリューム (24 時間):